Trince Raises €4M in Funding
Summary
Trince, a spin-off of Ghent University (UGent) developing innovative and efficient technology to insert genetic material into cells, raised €4m in funding. Led by Philip Mathuis, CEO, and Kevin Braeckmans, Chief Scientific Officer, Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company’s LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. The technology is the result of a decade of research by the team of Kevin Braeckmans and Stefaan De Smedt, professors at the Faculty of Pharmaceutical Sciences of UGent. The intellectual property will be transferred to Trince, and the spin-off will also receive a license on the results of joint research conducted by the University of Lille (CNRS, France) and UGent.
Funding
Review available funding amount, funding date, investors, and linked company information related to Trince Raises €4M in Funding in the interactive ISVWorld profile.